552 related articles for article (PubMed ID: 33472170)
21. Curcumol enhances the sensitivity of doxorubicin in triple-negative breast cancer via regulating the miR-181b-2-3p-ABCC3 axis.
Zeng C; Fan D; Xu Y; Li X; Yuan J; Yang Q; Zhou X; Lu J; Zhang C; Han J; Gu J; Gao Y; Sun L; Wang S
Biochem Pharmacol; 2020 Apr; 174():113795. PubMed ID: 31926937
[TBL] [Abstract][Full Text] [Related]
22. miR-1207-5p regulates the sensitivity of triple-negative breast cancer cells to Taxol treatment via the suppression of LZTS1 expression.
Hou X; Niu Z; Liu L; Guo Q; Li H; Yang X; Zhang X
Oncol Lett; 2019 Jan; 17(1):990-998. PubMed ID: 30655858
[TBL] [Abstract][Full Text] [Related]
23. circGFRA1 affects the sensitivity of triple-negative breast cancer cells to paclitaxel via the miR-361-5p/TLR4 pathway.
Zheng SR; Huang QD; Zheng ZH; Zhang ZT; Guo GL
J Biochem; 2021 Jul; 169(5):601-611. PubMed ID: 33481008
[TBL] [Abstract][Full Text] [Related]
24. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells.
Tanei T; Choi DS; Rodriguez AA; Liang DH; Dobrolecki L; Ghosh M; Landis MD; Chang JC
Breast Cancer Res; 2016 Jan; 18(1):6. PubMed ID: 26757880
[TBL] [Abstract][Full Text] [Related]
25. MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.
Liu X; Tang H; Chen J; Song C; Yang L; Liu P; Wang N; Xie X; Lin X; Xie X
Oncotarget; 2015 Aug; 6(24):20070-83. PubMed ID: 26036638
[TBL] [Abstract][Full Text] [Related]
26. Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.
Zhou Y; Yamamoto Y; Takeshita F; Yamamoto T; Xiao Z; Ochiya T
Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33467725
[TBL] [Abstract][Full Text] [Related]
27. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
[TBL] [Abstract][Full Text] [Related]
28. S-Adenosylmethionine Inhibits Cell Growth and Migration of Triple Negative Breast Cancer Cells through Upregulating MiRNA-34c and MiRNA-449a.
Coppola A; Ilisso CP; Stellavato A; Schiraldi C; Caraglia M; Mosca L; Cacciapuoti G; Porcelli M
Int J Mol Sci; 2020 Dec; 22(1):. PubMed ID: 33396625
[TBL] [Abstract][Full Text] [Related]
29. miR-744/eNOS/NO axis: A novel target to halt triple negative breast cancer progression.
El Kilany FH; Youness RA; Assal RA; Gad MZ
Breast Dis; 2021; 40(3):161-169. PubMed ID: 33749631
[TBL] [Abstract][Full Text] [Related]
30. MiR-6838-5p suppresses cell metastasis and the EMT process in triple-negative breast cancer by targeting WNT3A to inhibit the Wnt pathway.
Liu G; Wang P; Zhang H
J Gene Med; 2019 Dec; 21(12):e3129. PubMed ID: 31693779
[TBL] [Abstract][Full Text] [Related]
31. MiR-27a modulates radiosensitivity of triple-negative breast cancer (TNBC) cells by targeting CDC27.
Ren YQ; Fu F; Han J
Med Sci Monit; 2015 May; 21():1297-303. PubMed ID: 25943633
[TBL] [Abstract][Full Text] [Related]
32. Ursolic Acid Enhances Cytotoxicity of Doxorubicin-Resistant Triple-Negative Breast Cancer Cells via
Lu Q; Chen W; Ji Y; Liu Y; Xue X
Cancer Biother Radiopharm; 2022 Oct; 37(8):673-683. PubMed ID: 33493421
[No Abstract] [Full Text] [Related]
33. miR-200c/PAI-2 promotes the progression of triple negative breast cancer via M1/M2 polarization induction of macrophage.
Meng Z; Zhang R; Wang Y; Zhu G; Jin T; Li C; Zhang S
Int Immunopharmacol; 2020 Apr; 81():106028. PubMed ID: 31801690
[TBL] [Abstract][Full Text] [Related]
34. Nuclear epidermal growth factor receptor is a functional molecular target in triple-negative breast cancer.
Brand TM; Iida M; Dunn EF; Luthar N; Kostopoulos KT; Corrigan KL; Wleklinski MJ; Yang D; Wisinski KB; Salgia R; Wheeler DL
Mol Cancer Ther; 2014 May; 13(5):1356-68. PubMed ID: 24634415
[TBL] [Abstract][Full Text] [Related]
35. [miR-93-5p promotes invasion and migration of triple negative breast cancer cells by targeting FGD5].
Zhou D; Bai J; Hu Y; Zhang L; Zheng Q; Zhong W; Mu Q; Li H; Lyu S; Yin C
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2020 Sep; 36(9):794-801. PubMed ID: 32967763
[TBL] [Abstract][Full Text] [Related]
36. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib.
Wang X; Song H; Yu Q; Liu Q; Wang L; Liu Z; Yu Z
Oncol Rep; 2015 Feb; 33(2):526-32. PubMed ID: 25501339
[TBL] [Abstract][Full Text] [Related]
37. Tumor tissue microRNA expression in association with triple-negative breast cancer outcomes.
Liu Y; Cai Q; Bao PP; Su Y; Cai H; Wu J; Ye F; Guo X; Zheng W; Zheng Y; Shu XO
Breast Cancer Res Treat; 2015 Jul; 152(1):183-191. PubMed ID: 26062749
[TBL] [Abstract][Full Text] [Related]
38. EGFR and MEK Blockade in Triple Negative Breast Cancer Cells.
Maiello MR; D'Alessio A; Bevilacqua S; Gallo M; Normanno N; De Luca A
J Cell Biochem; 2015 Dec; 116(12):2778-85. PubMed ID: 25959272
[TBL] [Abstract][Full Text] [Related]
39. MiRNA-20a-5p promotes the growth of triple-negative breast cancer cells through targeting RUNX3.
Bai X; Han G; Liu Y; Jiang H; He Q
Biomed Pharmacother; 2018 Jul; 103():1482-1489. PubMed ID: 29864933
[TBL] [Abstract][Full Text] [Related]
40. LncRNA SNHG6/miR-125b-5p/BMPR1B Axis: A New Therapeutic Target for Triple-Negative Breast Cancer.
Lv Y; Lv X; Yang H; Qi X; Wang X; Li C; Shang X; Guo H; Zhang J; Zhang Y
Front Oncol; 2021; 11():678474. PubMed ID: 34026654
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
